MD - MEDNAX, Inc.

NYSE - NYSE Delayed Price. Currency in USD
15.96
-0.67 (-4.03%)
At close: 4:00PM EDT

16.50 +0.54 (3.41%)
After hours: 4:38PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close16.63
Open16.96
Bid15.92 x 800
Ask17.43 x 800
Day's Range15.86 - 16.96
52 Week Range7.37 - 28.66
Volume868,968
Avg. Volume1,523,119
Market Cap1.363B
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-15.41
Earnings DateJul 30, 2020 - Aug 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
21% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MEDNAX Plunges More Than 42% YTD: Will the Stock Rebound?
    Zacks

    MEDNAX Plunges More Than 42% YTD: Will the Stock Rebound?

    Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds prospects to revive its fortunes with the help of its initiatives and strong fundamentals.

  • Barrons.com

    Anterix and Bausch Holding See Activist Action

    Owl Creek Asset Management increased its stake in wireless-communications firm Anterix, while Paulson & Co. bought more Bausch stock.

  • Barrons.com

    2 Stocks to Short and 1 to Buy, According to a Short-Selling Maven

    Mark Roberts of Off Wall Street has been advising hedge funds for 30 years. Why he’s bearish on a software firm and a lubricants maker—and bullish on a gold stock.

  • MEDNAX Affiliate Ties Up With CDI to Improve Patient Care
    Zacks

    MEDNAX Affiliate Ties Up With CDI to Improve Patient Care

    MEDNAX's (MD) affiliate Jefferson Radiology collaborates with CDI for providing enhanced healthcare services to the Springfield community.

  • Jefferson Radiology, an Affiliate of MEDNAX, Develops New Collaborative Partnership with the Center for Diagnostic Imaging
    Business Wire

    Jefferson Radiology, an Affiliate of MEDNAX, Develops New Collaborative Partnership with the Center for Diagnostic Imaging

    Jefferson Radiology, an affiliate of MEDNAX and Center for Diagnostic Imaging launch new collaborative partnership.

  • MEDNAX Divests American Anesthesiology to Avoid Cash Losses
    Zacks

    MEDNAX Divests American Anesthesiology to Avoid Cash Losses

    MEDNAX (MD) sells its American Anesthesiology to NAPA for portfolio rationalization and averting the negative COVID-19 impact.

  • Moody's

    MEDNAX, Inc. -- Moody's changes MEDNAX's outlook to negative from stable, affirms B1 CFR

    Moody's Investors Service ("Moody's") changed MEDNAX, Inc.'s ("MEDNAX") outlook to negative from stable. At the same time, Moody's affirmed the company's B1 Corporate Family Rating, the B1-PD Probability of Default Rating and the B1 ratings on its unsecured bonds due in 2023 and 2027. There is no change to the company's SGL-2 Speculative Grade Liquidity Rating.

  • MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y
    Zacks

    MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y

    MEDNAX's (MD) Q1 results reflect the coronavirus adversities that drained its revenues and volumes.

  • Thomson Reuters StreetEvents

    Edited Transcript of MD earnings conference call or presentation 7-May-20 2:00pm GMT

    Q1 2020 MEDNAX Inc Earnings Call

  • Mednax Inc (MD) Q1 2020 Earnings Call Transcript
    Motley Fool

    Mednax Inc (MD) Q1 2020 Earnings Call Transcript

    MD earnings call for the period ending March 31, 2020.

  • Benzinga

    Mednax: Q1 Earnings Insights

    Shares of Mednax (NYSE:MD) fell 10% after the company reported Q1 results.Quarterly Results Earnings per share fell 50.77% over the past year to $0.32, which missed the estimate of $0.56.Revenue of $845,918,000 lower by 0.62% year over year, which missed the estimate of $856,420,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 07, 2020View more earnings on MDWebcast URL: https://edge.media-server.com/mmc/p/pfdzzn4qRecent Stock Performance 52-week high: $29.97Company's 52-week low was at $7.37Price action over last quarter: down 35.97%Company Description Mednax Inc provides physician services, which include newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology, and other pediatric subspecialty care. The firm operates in six segments: neonatal and other pediatric subspecialties, anesthesia, maternal-fetal, pediatric cardiology, radiology, and other services. The neonatal segment contributes the largest proportion of the firm's revenue. Mednax generates virtually all of its revenue in the United States, with over half of its revenue from operations in five states: Texas, North Carolina, Georgia, Tennessee, and Florida. Contracted managed care payors contribute the majority of net collections.See more from Benzinga * Endo International: Q1 Earnings Insights * Newmark Group: Q1 Earnings Insights * Cooper Tire & Rubber: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Mednax (MD) Lags Q1 Earnings Estimates
    Zacks

    Mednax (MD) Lags Q1 Earnings Estimates

    Mednax (MD) delivered earnings and revenue surprises of -23.81% and 1.29%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • MEDNAX Reports First Quarter Results
    Business Wire

    MEDNAX Reports First Quarter Results

    MEDNAX Reports First Quarter Results Completes Sale of American Anesthesiology to North American Partners in Anesthesia

  • Analysts Estimate Mednax (MD) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Mednax (MD) to Report a Decline in Earnings: What to Look Out for

    Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • MEDNAX 2020 First Quarter Conference Call/Webcast Scheduled for Thursday, May 7, 2020
    Business Wire

    MEDNAX 2020 First Quarter Conference Call/Webcast Scheduled for Thursday, May 7, 2020

    MEDNAX 2020 First Quarter Conference Call/Webcast Scheduled for Thursday, May 7, 2020

  • MEDNAX Plunges More Than 54% YTD: Will the Stock Rebound?
    Zacks

    MEDNAX Plunges More Than 54% YTD: Will the Stock Rebound?

    Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds high prospects to revive its fortunes by virtue of its solid fundamentals.

  • Moody's

    Sound Inpatient Physicians, Inc. -- Moody's announces rating actions on 9 healthcare staffing, radiology and imaging companies

    Moody's Investors Service, ("Moody's") today announced rating actions on 9 US healthcare services companies with businesses in physician staffing, travel nurse, locum tenens, radiology and diagnostic imaging to reflect the expected impact of business disruption caused by the coronavirus outbreak. As providers of various types of healthcare services, these companies are exposed to declining demand for their services due to factors including the postponement of elective procedures, lower emergency department volumes and closure of many non-emergent healthcare facilities. The US healthcare services sector has been one of the sectors affected by the shock given government and health association guidance to postpone all non-emergent healthcare services and take self-isolation measures.

  • MEDNAX Provides Updates Related to Coronavirus Pandemic
    Zacks

    MEDNAX Provides Updates Related to Coronavirus Pandemic

    MEDNAX (MD) takes several steps to help fight the COVID-19 pandemic.

  • MEDNAX Responds to Coronavirus Pandemic
    Business Wire

    MEDNAX Responds to Coronavirus Pandemic

    MEDNAX, Inc. today announced the proactive steps it has been taking in response to the rapidly evolving Coronavirus (COVID-19) pandemic.

  • Hedge Funds Have Never Been This Bullish On Mednax Inc. (MD)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Mednax Inc. (MD)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • Select Medical Revokes Full-Year View Amid Coronavirus Blues
    Zacks

    Select Medical Revokes Full-Year View Amid Coronavirus Blues

    Plagued by business uncertainty from the coronavirus outbreak, Select Medical (SEM) ditches its 2020 earnings guidance.

  • HCA Healthcare Makes Cost-Control Efforts Amid Coronavirus Woes
    Zacks

    HCA Healthcare Makes Cost-Control Efforts Amid Coronavirus Woes

    HCA Healthcare (HCA) trims headcount to contain costs as its revenues are under pressure.

  • Reuters

    GCP Applied Technologies adds two new independent directors in fight with Starboard

    GCP Applied Technologies said on Friday that its slate of board nominees will include two new independent directors and that it will expand the size of the board by one to 10 members. The Cambridge, Massachusetts-based chemical company is striking back at activist investor Starboard Value hours after the hedge fund announced on Thursday that it will push forward with its proxy fight and nominated eight directors. GCP named Armand Lauzon and John McPherson, executives with construction products expertise, as director candidates.

  • The 5 Best Stocks (And 5 Worst) of the Coronavirus Correction
    Kiplinger

    The 5 Best Stocks (And 5 Worst) of the Coronavirus Correction

    The rapid spread of the COVID-19 coronavirus is wreaking havoc across the equity market. The S&P; 500 lost nearly 13% from Feb. 19 to Feb. 28 - the fastest descent from all-time highs into correction territory in market history.Virtually all stocks have been affected by the growing scare. The worst stocks of the correction so far have all been pummeled by issues stemming from coronavirus - in particular, from the resulting rout in oil prices. Most of the best stocks (a handful of companies that managed to finish in the black) delivered gains based on the revenue opportunity that COVID-19 potentially represents, though a couple benefited from completely unrelated good news.To get a sense of what worked and what didn't, we screened the Russell 1000 Index, which includes the thousand largest companies on the U.S. equity market, for the best- and worst-performing stocks during the steep drawdown from Feb. 19 to Feb. 28. Both the Russell 1000 and S&P; 500 lost 12.8% over that period - predictably, biotechnology, travel and energy stocks were well represented among the stocks with the biggest moves.There were also a couple of pleasant surprises.Have a look at the five worst and five best stocks coming out of the market's epic February plunge. SEE ALSO: 11 Best Stocks to Ride Out the Coronavirus Outbreak